CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1880-4233
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy ; day:3 ; month:7 ; year:2018 ; pages:1-11
Breast cancer ; (3.7.2018), 1-11
- Creator
-
Tokunaga, Eriko
- Contributor
-
Fujita, Aya
Takizawa, Katsumi
Baba, Kimiko
Akiyoshi, Sayuri
Nakamura, Yoshiaki
Ijichi, Hideki
Masuda, Takanobu
Koga, Chinami
Tajiri, Wakako
Ohno, Shinji
Taguchi, Kenichi
Ishida, Mayumi
SpringerLink (Online service)
- DOI
-
10.1007/s12282-018-0888-y
- URN
-
urn:nbn:de:101:1-2018090320074394551744
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tokunaga, Eriko
- Fujita, Aya
- Takizawa, Katsumi
- Baba, Kimiko
- Akiyoshi, Sayuri
- Nakamura, Yoshiaki
- Ijichi, Hideki
- Masuda, Takanobu
- Koga, Chinami
- Tajiri, Wakako
- Ohno, Shinji
- Taguchi, Kenichi
- Ishida, Mayumi
- SpringerLink (Online service)
Other Objects (12)
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer
A Brief Review of Treatment Options for Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer
Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer
Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer
A Brief Review of Treatment Options for Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer
Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer
Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer
A Brief Review of Treatment Options for Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer
Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer
Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer